NDAINJECTIONINJECTABLE
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INNOHEP (tinzaparin sodium) is a low-molecular-weight heparin (LMWH) administered by subcutaneous injection for the treatment of venous thromboembolism, deep vein thrombosis, and related thromboembolic disorders. It works by enhancing the inhibition of Factor Xa and thrombin through antithrombin III, preferentially inhibiting Factor Xa to prevent thrombus formation. This established anticoagulant has been the standard of care in acute VTE management for over two decades.
LOE Approaching
Declining
Facing significant erosion from newer oral anticoagulants; brand team focused on defending remaining market share and managing transition strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
Started Aug 2010
900 enrolled
Venous Thromboembolism
Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis
Started Dec 2005
541 enrolled
Deep Vein Thrombosis
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Started Feb 2004
40 enrolled
Primary Brain Tumor
Career Relevance
Careers linked to INNOHEP are concentrated in commercial operations focused on declining-brand management, reimbursement defense, and market-share retention rather than growth or innovation. Positions involve managing product transition, payer negotiations, and cost-containment strategies as the market shifts to oral anticoagulants.
Worked on INNOHEP at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.